XML 19 R9.htm IDEA: XBRL DOCUMENT v3.25.3
Financial Instruments
9 Months Ended
Sep. 30, 2025
Investments, All Other Investments [Abstract]  
Financial Instruments Financial Instruments
Cash, Cash Equivalents and Marketable Securities

The following tables summarize our cash, cash equivalents and marketable securities balances in our Condensed Consolidated Balance Sheets as of September 30, 2025 and Consolidated Balance Sheets as of December 31, 2024 (in thousands):
Reported as:
September 30, 2025Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair ValueCash and Cash Equivalents
Cash$797,412 $— $— $797,412 $797,412 
Money market funds
190,785 — — 190,785 190,785 
Certificate of deposits
16,392 — — 16,392 16,392 
Total$1,004,589 $— $— $1,004,589 $1,004,589 


Reported as:
December 31, 2024Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair ValueCash and Cash Equivalents
Cash$752,423 $— $— $752,423 $752,423 
Money market funds291,464 — — 291,464 291,464 
Total$1,043,887 $— $— $1,043,887 $1,043,887 

We had no short-term or long-term marketable securities as of September 30, 2025 or December 31, 2024.

Fair Value Measurements

Fair value is an exit price, representing the amount that would be received from selling an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. We use the U.S. GAAP fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. This hierarchy requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value:

Level 1 — Inputs to the valuation techniques that are quoted prices in active markets for identical assets or liabilities.

Level 2 — Inputs to the valuation techniques that are other than quoted prices but are observable for the assets or liabilities, either directly or indirectly.

Level 3 — Inputs to the valuation techniques that are unobservable for the assets or liabilities.

The following tables summarize our financial assets measured at fair value as of September 30, 2025 and December 31, 2024 (in thousands):
Description
Balance as of
September 30, 2025
Level 1
Cash equivalents:
Money market funds$190,785 $190,785 
Certificate of deposits
16,392 16,392 
Total
$207,177 $207,177 
Description
Balance as of
December 31, 2024
Level 1
Cash equivalents:
Money market funds$291,464 $291,464 
Total
$291,464 $291,464 

Accounts Receivable Factoring

We enter into factoring transactions on a non-recourse basis with financial institutions to sell certain of our non-U.S. accounts receivable. We account for these transactions as sales of financial assets and include the cash proceeds as a part of our cash flows from operations in the Condensed Consolidated Statements of Cash Flows. Total accounts receivable sold under factoring arrangements were $10.0 million and $8.2 million during the three months ended September 30, 2025 and 2024, respectively, and $34.6 million and $34.2 million during the nine months ended September 30, 2025 and 2024, respectively. Factoring fees on the sales of receivables were recorded in Other income (expense), net in our Condensed Consolidated Statements of Operations and were not material.

Investments in Privately Held Companies

Our investments in privately held companies in which we cannot exercise significant influence and do not own a majority equity interest or otherwise control are accounted for as investments in equity securities. We have elected to account for all investments in equity securities in accordance with the measurement alternative. Under the measurement alternative, we record the value of our investments in equity securities at cost, minus impairment, if any. Additionally, we adjust the carrying value of our investments in equity securities for observable transactions for identical or similar investments of the same issuer.

On April 24, 2023 and April 22, 2024, we entered into Subscription Agreements (the “Subscription Agreements”) with Heartland Dental Holding Corporation (“Heartland”). Pursuant to the Subscription Agreements we acquired less than a 5% equity interest in Heartland through the purchase of Class A Common Stock for $150 million in total. In the fourth quarter of 2024, we recorded a $6 million increase to the carrying value of our investment, which increased the total carrying value of our investment in Heartland to $156 million.

On December 19, 2024 and June 5, 2025, we entered into Subscription Agreements (the “Smile Doctors Subscription Agreements”) with New SD Holding Company, L.P. (“SD Holding Company”). Pursuant to the Smile Doctors Subscription Agreements we acquired less than a 3% equity interest in SD Holding Company through the purchase of Class A Common Units for $40 million in total. SD Holding Company owns a controlling interest, through intermediary entities, in Smile Doctors, LLC.

Based on a review of the relevant facts and circumstances, primarily observable transactions for identical investments, we determined that no adjustments to the carrying values of our investments were necessary for the three or nine months ended September 30, 2025.

Our investments in privately held companies in which we can exercise significant influence are accounted for as equity method investments. We have elected to account for our equity method investments under the fair value option.

The carrying value of our investments in equity securities and equity method investments are reported in our Condensed Consolidated Balance Sheets as Other assets and any price adjustments or impairment, if any, are recorded in Other income (expense), net in our Condensed Consolidated Statements of Operations.

Derivatives Not Designated as Hedging Instruments

We enter into foreign currency forward contracts to minimize the short-term impact of foreign currency exchange rate fluctuations on certain assets and liabilities. These forward contracts are classified within Level 2 of the fair value hierarchy. As a result of the settlement of foreign currency forward contracts, we recognized a net gain of $3.3 million and a net loss of $24.5 million during the three months ended September 30, 2025 and 2024, respectively, and a net loss of $35.3 million and a net gain $2.7 million, respectively, during the nine months ended September 30, 2025 and 2024. Recognized gains and losses from the settlement of foreign currency forward contracts are recorded in Other income (expense), net in our Condensed Consolidated Statements of Operations. As of September 30, 2025 and December 31, 2024, the fair value of outstanding foreign exchange forward contracts was not material.
The following tables present the gross notional value of all our foreign exchange forward contracts outstanding as of September 30, 2025 and December 31, 2024 (in thousands):
September 30, 2025
Local Currency AmountNotional Contract Amount (USD)
Euro€159,000$186,840 
Canadian DollarC$82,50059,356 
British Pound£39,70053,324 
Polish ZlotyPLN175,00048,036 
Israeli ShekelILS94,10028,452 
Japanese Yen¥3,300,00022,374 
Brazilian RealR$92,30017,189 
Swiss FrancCHF5,6007,048 
New Taiwan DollarNT$106,3003,482 
Australian DollarA$4,8003,177 
New Zealand DollarNZ$4,3002,495 
Korean Won₩3,200,0002,283 
Chinese Yuan¥15,0002,108 
Total notional contract amount$436,164 

December 31, 2024
Local Currency AmountNotional Contract Amount (USD)
Euro€176,080$183,172 
Polish ZlotyPLN283,00068,633 
Canadian DollarC$97,00067,446 
British Pound£37,60047,090 
Israeli ShekelILS90,05524,740 
Chinese Yuan¥164,50022,417 
Brazilian RealR$83,10013,327 
Japanese Yen¥2,000,00012,778 
Swiss FrancCHF5,7006,314 
New Zealand DollarNZ$7,0003,924 
Czech KorunaKč72,8003,004 
Australian DollarA$3,8002,355 
New Taiwan DollarNT$58,7001,786 
Korean Won₩2,000,0001,361 
Total notional contract amount$458,347